Toxic nephropathy — kidney injury from drugs, metals, toxins, or endogenous metabolites — is challenging because of the range of culprits and the risk of progression to chronic kidney disease. The most striking recent advance is a genetically targeted therapy.
APOL1-targeted therapy
Two variants in the APOL1 gene, common in people of recent African ancestry, drive an aggressive proteinuric nephropathy (APOL1-mediated kidney disease) in which environmental "second hits" such as interferon-driven inflammation trigger podocyte injury. Inaxaplin, a first-in-class oral APOL1 channel inhibitor, reduced proteinuria by 47.6% at 13 weeks in a Phase 2 study of patients with two APOL1 variants and FSGS. It has since advanced into the Phase 3 portion of the adaptive AMPLITUDE trial (now including adolescents), with an eGFR-slope primary endpoint, breakthrough-therapy designation, and accelerated approval anticipated — a landmark example of precision nephrology matched to genotype.
Supportive and general management
The cornerstones remain prompt withdrawal of the offending agent, hydration, and correction of electrolyte and acid-base disturbances, with renal replacement therapy for refractory derangements. Specific measures include N-acetylcysteine and sodium bicarbonate in selected settings (with debated benefit), and chelation for heavy-metal nephropathy. For limiting progression across CKD etiologies — including toxic causes — SGLT2 inhibitors and mineralocorticoid receptor antagonists (finerenone) reduce hyperfiltration, inflammation, and fibrosis, and antioxidant strategies are under study.
| Strategy | Role | Note |
|---|---|---|
| Inaxaplin (APOL1 inhibitor) | APOL1-mediated kidney disease | Phase 3 (AMPLITUDE); accelerated approval anticipated |
| Stop offending agent | All toxic nephropathy | Essential to halt injury |
| Hydration, electrolyte correction | Supportive | Standard of care |
| Chelation | Heavy-metal nephropathy | Agent-specific |
| SGLT2 inhibitors / MRAs | Slow CKD progression | Cross-etiology benefit |
Further reading: inaxaplin Phase 2 (Egbuna et al., NEJM 2023) and AMPLITUDE Phase 3 (ongoing); toxic tubulointerstitial nephropathy core curriculum (AJKD 2024).